Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From ReCode Therapeutics
Private Company Edition: ReCode’s series B venture capital round grew for a third time, now totaling $260m for precision genetic medicines. Also, DalCor closed an $80m series D, manufacturer Nephron amassed $350m, Hyku launched with a $56m seed financing and Magnet emerged with $50m.
It is ‘up in the air’ what manufacturers and the FDA will have to do if an appeals court does not stay the injunction against mifepristone. More than 400 biopharma industry leaders sign a letter calling for reversal of Judge Kacsmaryk’s order and supporting the FDA’s regulatory authority.
Recent financings, including the $150m launch of Pathalys and a planned $100m IPO for Mineralys, illustrate the reality of biopharma funding in 2023 – that having near-term clinical trial milestones are key to fundraising this year. Companies with dwindling cash are conserving the funds they have left.
Daily notebook from the J.P. Morgan Healthcare Conference: Big pharma execs weigh in on business development strategy, Sage CEO Barry Green discusses how the Inflation Reduction Act should spur deal-making and bluebird talks about gene therapy commercialization plans.
- Drug Delivery
- Antisense, Oligonucleotides
- Large Molecule
- Nanotechnology, Chips, etc.
Drug Discovery Tools
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.